Synergic cancer chemo-immunotherapy comprising combined doxorubicin and siRNA targeting CD47 co-delivered by a bola-amphiphilic dendrimer

Key Points

• The aim is to explore a new cancer treatment strategy that enhances chemotherapy and boosts the immune response against tumors.
• Developed a bola-amphiphilic dendrimer to co-deliver doxorubicin and siRNA.
• Targeted CD47 to enhance macrophage phagocytosis of cancer cells.
• Conducted in vivo tests to evaluate the combined treatment's efficacy.
• The treatment improved antitumor immunity.
• Significantly enhanced phagocytic activity of macrophages against cancer cells.
• Combination therapy showed greater efficacy compared to conventional therapies.